Join Now

# Latest News

Submit News

31 October 2012 at 13:13 - Posted by AfricaFinance

Wealth of worldwide evidence on Pradaxa® including first clinical data on long-term efficacy and safety of a novel oral anticoagulant to be presented at AHA Scientific Sessions


337

INGELHEIM, Germany - Wednesday, October 31st 2012 [ME NewsWire]

    Presentation of RELY-ABLE® study results: First and only long-term efficacy & safety data on a novel oral anticoagulant for stroke prevention in atrial fibrillation (AF) to be announced in the Clinical Science: Special Reports session
    New sub-analyses from the 18,000 patient landmark trial RE-LY® also discussed
    Real-world clinical data for VTE prevention in total knee or hip replacement to be presented

(BUSINESS WIRE)-- For Non-US, Non-UK & Non-Canadian Media Only

Widely anticipated results from RELY-ABLE®, the first long-term follow-up study of a novel oral anticoagulant treatment for stroke prevention in AF, will be among the numerous clinical reports on Pradaxa® (dabigatran etexilate) to be presented at the American Heart Association’s (AHA) Scientific Sessions in Los Angeles from 3-7 November.1 The wealth of evidence being presented for Pradaxa® at this year’s AHA sheds light on the clinical, long-term and real-world benefits of the treatment for patients at risk for thromboembolic events worldwide.

The RELY-ABLE® results presented are the first randomized follow-up data indicating how a novel oral anticoagulant is performing over more than four years of treatment duration.1These important results will provide knowledge on the consistency of benefits offered by the treatment and support physicians in their search for optimal stroke protection. RELY-ABLE® is the long-term extension study of the RE-LY® trial, one of the largest phase III trials to investigate the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.1-3

RELY-ABLE® oral presentation information:

Title
         

Lead Author
         

Presentation details
    

Randomized Comparison  of the Effects of Two  Doses of Dabigatran  Etexilate on Clinical  Outcomes Over 4.3 Years:  Results of the RELY-ABLE  Double-blind  Randomized  Trial
         

Stuart J Connolly,  McMaster Univ,  Hamilton, ON,  Canada
         

CS.04. Clinical Science:  Special Reports: Valvular  Heart Disease, PAD,  Atrial Fibrillation:  International  Perspectives

Wed, Nov 7,  11:55 - 12:05 PT
    
                               

The RELY-ABLE® study conclusions will be discussed during an exclusive online data webcast available on demand for medical media from 9 a.m. CET on Thursday 8 November –www.newshome.com.

Additional studies on Pradaxa® being presented at the AHA Scientific Sessions

In addition to RELY-ABLE®, several reports including novel RE-LY® subanalyses, clinical real-world experience and preclinical studies on Pradaxa® will be presented at the AHA Scientific Sessions. Of particular note will be results from real-world practice examining the safety and efficacy of Pradaxa® for the prevention of venous thromboembolism after total knee or hip replacement,4 as well as updates from the Boehringer Ingelheim Research & Development Programme regarding an antibody fragment antidote for rapid reversal of the anticoagulant effect of Pradaxa®.5

Further Pradaxa® abstracts being presented at AHA:*

ATRIAL FIBRILLATION

RE-LY® trial sub-analyses:

    Comparison of Dabigatran versus Warfarin in Diabetic Patients with Atrial Fibrillation: Results from the RE-LY Trial Lead Author: H. Darius, Poster No. 15937, Sunday 4 November, 3:00 p.m. - 4:30 p.m.
    Dabigatran Versus Warfarin in Very Elderly Patients with Atrial Fibrillation: Results from the RE-LY Trial Lead Author: M. Coppens, Oral Presentation 15537, Monday 5 November, 9:30 a.m. - 9:45 a.m.
    Balancing the Benefits and Risks of Two Doses of Dabigatran Compared with Warfarin in Atrial Fibrillation Lead Author: J. Eikelboom, Presentation 14433, 11:30 a.m. - 11:45 a.m.
    Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation - A RE-LY Substudy Lead Author: Z. Hijazi, Oral Presentation 14808, Tuesday 6 November, 4:45 p.m. - 5:00 p.m.

Other key AF abstracts:

    Cluster Randomized Controlled Trial to Test The Effect of a Multifaceted Comprehensive Cardiovascular Care Intervention on Clinical Outcomes in Atrial Fibrillation Patients Receiving Dabigatran Lead Author: R. Nieuwlaat, Oral Presentation 12618, Monday 5 November, 9:00 a.m. - 9:15 a.m.
    Regional Variation in Ischemic Stroke Rates and Oral Anticoagulant Use Among the Non-Valvular Atrial Fibrillation Medicare Population Lead Author: K. Fitch, Poster No. 12992, Tuesday 6 November, 9:30 a.m. – 11:00 a.m., presented by K. Siu
    Association between Outpatient Visits Following Hospital Discharge and Readmissions among Medicare Beneficiaries with Atrial Fibrillation Lead Author: M. Hubbard, Poster No. 11367, Tuesday 6 November, 9:30 a.m. - 11:00 a.m., presented by K. Siu
    Incidence of Bleeding Events in Patients with Atrial Fibrillation Lead Author: T. Murray-Thomas, Poster No. 14178, Tuesday 6 November, 3:00 p.m. - 4:30 p.m., presented by A. Clemens
    Cost-Effectiveness of Dabigatran Etexilate versus Rivaroxaban for Stroke and Systemic Embolism Risk Reduction in Atrial Fibrillation: A US Third Party Payer Perspective Lead Author: D. Walker, Poster No. 14964, Wednesday 7 November, 9:30 a.m. – 11:00 a.m.

Primary prevention of VENOUS THROMBOEMBOLISM in patients after total knee or hip replacement surgery:

    Safety and Efficacy of Once Daily 220 mg Dabigatran Etexilate in a Real-World Non-Interventional Study of More Than 5000 Patients After Total Knee or Hip Replacement Lead Author: N. Rosencher, Poster No. 10001, 3:00 p.m. - 4:30 p.m.

comments powered by Disqus